Hikma Pharmaceuticals (OTCMKTS:HKMPF) Stock Rating Lowered by Zacks Investment Research

Hikma Pharmaceuticals (OTCMKTS:HKMPFGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday, Zacks.com reports.

According to Zacks, “Hikma Pharmaceuticals PLC develops, manufactures and markets pharmaceutical products. Its brand portfolio includes branded, injectables and generic. Branded segment offers dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system, oncology and respiratory. Injectables segment offers dosage for CNS, controlled substances, anti-infective, cardiovascular and oncology in form of liquid, semi-liquid and powdered form. Generics segment offers dosage for therapeutic including analgesic, anti-infective, anti-inflammatory, cardiovascular, CNS, respiratory and hormonal. Hikma Pharmaceuticals PLC is based in London, the United Kingdom. “

A number of other brokerages also recently issued reports on HKMPF. JPMorgan Chase & Co. lowered their price target on Hikma Pharmaceuticals from GBX 3,000 ($37.48) to GBX 2,900 ($36.23) in a report on Wednesday, March 2nd. Morgan Stanley downgraded Hikma Pharmaceuticals from an “overweight” rating to an “equal weight” rating in a report on Thursday, March 3rd. Finally, Peel Hunt raised Hikma Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, January 20th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $1,465.50.

HKMPF stock opened at $28.00 on Wednesday. The company’s 50 day moving average price is $26.87 and its 200 day moving average price is $28.49. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.38 and a current ratio of 2.06. Hikma Pharmaceuticals has a fifty-two week low of $24.30 and a fifty-two week high of $37.70.

About Hikma Pharmaceuticals (Get Rating)

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.

Further Reading

Get a free copy of the Zacks research report on Hikma Pharmaceuticals (HKMPF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Hikma Pharmaceuticals (OTCMKTS:HKMPF)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.